Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy

@article{Heath2000ClinicalPO,
  title={Clinical Potential of Matrix Metalloprotease Inhibitors in Cancer Therapy},
  author={Dr Elisabeth I. Heath and Louise B. Grochow},
  journal={Drugs},
  year={2000},
  volume={59},
  pages={1043-1055}
}
Matrix metalloproteases (MMP) are a family of enzymes that contribute to the degradation of the extracellular matrix. The destruction of the extracellular matrix eventually leads to tumour invasion, metastasis and angiogenesis. Realising this mechanism of action, there is tremendous potential for inhibitors of MMP in cancer therapy. Extensive preclinical data have shown that administration of matrix metalloprotease inhibitors (MMPI) to different animal models results in a reduction in primary… CONTINUE READING
23 Citations
58 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 58 references

Aphase I pharmacokinetic evaluation of the matrix metalloprotease (MMP) inhibitor AG3340 in combination with mitoxantrone and prednisone in patients with advanced prostate cancer [abstract no. 1244

  • G Wilding, E Small, CollierM
  • Proceed 1054 Heath & Grochow © Adis International…
  • 2000
1 Excerpt

Marimastat in patients with hormone refractory prostate cancer: a dose-finding study [abstract no. 1126

  • P Boasberg, Harbaugh, M. Eisenberger
  • Proceedings of the 33th Annual Meeting
  • 2000
1 Excerpt

360 Patient meta - analysis of studies of marimastat . A novel matrix metalloproteinase inhibitor

  • A Millar
  • Clin Cancer Res
  • 1999

A phase I study of marimastat in combination with doxorubicin and cyclophosphamide in patients with metastatic breast cancer [abstract no. 476

  • W Gradishar, J VonRoenn, M Cobleigh
  • Proceedings of the 35th Annual Meeting of the…
  • 1999
1 Excerpt

A phase I study of the matrix metalloproteinase inhibitor MM1270 (previously termed CGS27023A) with 5FU and folinic acid [abstract no. 803

  • M Eatock, J Cassidy, J. Johnson
  • Proceedings of the 35th Annual Meeting of the…
  • 1999
1 Excerpt

A phase I, safety, and pharmacokinetic trial of BMS-275291, amatrixmetalloproteinase inhibitor (MMPI), in patients with advanced or metastatic cancer [abstract no. 0726

  • N Rizvi, J Humphrey, J Ness
  • Proceedings of the 90th Annual Meeting of the…
  • 1999
1 Excerpt

AG3340 and carboplatin increase survival in an orthotopic nude rat model of primary and metastatic human lung cancer [abstract no. 1946

  • MR Johnston, JM Mullen, M Pagura
  • Proceedings of the 90th Annual Meeting of the…
  • 1999
1 Excerpt

Aphase I and pharmacologic study of the oral matrix metalloproteinase inhibitor, BAY 129566 in combination with paclitaxel and carboplatin [abstract no. 617

  • A Tolcher, EK Rowinsky, J. Rizzo
  • Proceedings of the 35th Annual Meeting of the…
  • 1999
1 Excerpt

Similar Papers

Loading similar papers…